NULYTELY
LOE Approachingpolyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride
NDAORALFOR SOLUTION
Approved
Apr 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
NULYTELY (polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride) by R-Pharm US is osmotic activity [moa]. First approved in 1991.
Drug data last refreshed 6m ago · AI intelligence enriched 6m ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NULYTELY is an oral osmotic laxative solution containing polyethylene glycol 3350 and electrolytes designed for bowel cleansing prior to colonoscopy and other GI procedures. It works through osmotic activity to draw water into the intestinal lumen, producing rapid bowel evacuation without systemic absorption. This is a mature, established product in the gastrointestinal preparation category.
$0.002BPart D
LOE ApproachingStable
Mature market position with moderate spending; teams are likely focused on cost management and operational efficiency rather than growth initiatives.
Mechanism of Action
Osmotic Activity
Pharmacologic Class:
Osmotic Laxative
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NULYTELY offers stable but limited career advancement; roles center on defending market share, managing formulary access, and operational efficiency in a commoditized category. This is ideal for professionals seeking structured, lower-risk positions in a mature therapeutic area rather than entrepreneurial growth opportunities.
Product Manager (Specialty / Mature Products)
Worked on NULYTELY at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.